Concentrix Corp — Director's Dealing 2020

Dec 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Concentrix Corp (CNXC)
CIK: 0001803599
Period of Report: 2020-12-01

Reporting Person: POLK DENNIS (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-01	Common Stock	J	43966	—	Acquired	43966	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-01	Employee Stock Option (Right to Buy)	$61.83	J	10584	Acquired	2023-10-03	Common Stock (10584.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$62.9	J	15514	Acquired	2024-10-07	Common Stock (15514.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$89.21	J	11235	Acquired	2025-10-06	Common Stock (11235.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$112.08	J	13778	Acquired	2026-10-04	Common Stock (13778.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$128.67	J	12188	Acquired	2027-10-03	Common Stock (12188.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$96.46	J	37851	Acquired	2028-04-09	Common Stock (37851.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$76.01	J	71003	Acquired	2028-10-11	Common Stock (71003.0)	Direct
2020-12-01	Employee Stock Option (Right to Buy)	$110.44	J	46588	Acquired	2029-10-02	Common Stock (46588.0)	Direct

Footnotes

F1: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

F2: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F3: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

F4: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

F5: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018 and vests as to 1/60th of the shares monthly thereafter.

F6: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

F7: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.